Update on the phase IV confirmatory study of Aduhelm for Alzheimer’s disease – Biogen + Eisai
Biogen Inc. and Eisai Co., Ltd. provided an important update on the continuing progress of the Phase IV post-marketing confirmatory study of Aduhelm (aducanumab-avwa) 100 mg/mL injection for… read more.